Large Outflow of Money Witnessed in Cambrex Corporation

Cambrex Corporation (CBM) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($3.27 million) and the uptick to downtick ratio was 0.43. The transaction value on upticks was $2.46 million and on downticks, the transaction value was $5.73 million. The transaction value of block trades during downticks was $3.18 million. The money flow was negative ($3.18 million), indicating the traders were booking profit on the price strength. Cambrex Corporation (CBM) rose $0.14 at $57.88, during intraday Monday , a rise of 0.24% over the previous days close.


Cambrex Corporation is up 30.59% in the last 3-month period. Year-to-Date the stock performance stands at 23.3%. Shares of Cambrex Corporation rose by 5.54% in the last five trading days and 20.46% for the last 4 weeks. In a related news, The director, of Cambrex Corp, Korb William B had unloaded 3,420 shares at $55 per share in a transaction on July 11, 2016. The total value of transaction was $188,100. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Cambrex Corporation (NYSE:CBM): stock turned positive on Monday. Though the stock opened at $57.73, the bulls momentum made the stock top out at $58.19 level for the day. The stock recorded a low of $57.35 and closed the trading day at $58.06, in the green by 0.55%. The total traded volume for the day was 316,404. The stock had closed at $57.74 in the previous days trading.

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Companys customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Companys products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and, to a lesser extent, other fine chemicals. Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *